Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors

Cancer Research

Volumn 72, Issue 1, 2012, Pages 346-355

  Carothers, Adelaide M ^a   Rizvi, Hira ^a   Hasson, Rian M ^a   Heit, Yvonne I ^a   Davids, Jennifer S ^a   Bertagnolli, Monica M ^a   Cho, Nancy L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIVIN RECEPTOR LIKE KINASE 1; APC PROTEIN; BETA CATENIN; BETA1 INTEGRIN; BMI1 PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD34 ANTIGEN; ENDOGLIN; F ACTIN; HERMES ANTIGEN; KI 67 ANTIGEN; NOTCH1 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THY 1 ANTIGEN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADENOMATOUS POLYP; ADIPOCYTE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARTILAGE CELL; CELL DENSITY; CELL DIFFERENTIATION; CELL RENEWAL; CELL TYPE; CONTROLLED STUDY; DESMOID TUMOR; FAMILIAL ADENOMATOUS POLYPOSIS; FIBROCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MESENCHYMAL STROMA CELL; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SOMATIC MUTATION; TUMOR CELL; WOUND HEALING;

CELL LINE, TUMOR; FIBROMATOSIS, AGGRESSIVE; HUMANS; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STROMAL CELLS; MUTATION; WOUND HEALING;

EID: 84855389100     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2819     Document Type: Article

References (49)

1. Klemmer S, Pascoe L, DeCosse J. Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. Am J Med Genet 1987;28:385-92. (Pubitemid 18007184)
2. Rodriquez-Bigas MA, Mahoney MC, Karakousis CP, Petrelli NJ. Desmoid tumors in patients with familial adenomatous polyposis. Cancer 1994;74:1270-4. (Pubitemid 24301779)
3. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-20. (Pubitemid 38128287)
4. Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extra-abdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-9. (Pubitemid 35351145)
5. Bertagnolli MM, Morgan JA, Fletcher CD, Raut CP, Dileo P, Gill RR, et al. Multimodality treatment of mesenteric desmoid tumors. Eur J Cancer 2008;44:2404-10.
6. Alfaro MP, Pagni M, Vincent A, Atkinson J, Hill MF, Cates J, et al. The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A 2008;105:18366-71.
7. Latchford A, Volikos E, Johnson V, Rogers P, Suraweera N, Tomlinson I, et al. APC mutations in FAP-associated desmoid tumours are nonrandom but not "just right". Hum Mol Genet 2007;16:78-82. (Pubitemid 46152545)
8. Salas S, Chibon F, Noguchi T, Terrier P, Ranchere-Vince D, Lagarde P, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010;49:560-8.
9. Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, et al. Predominance of b-catenin mutations and β-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18:6873-82.
10. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the β-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518-27.
11. Mills BG, Frausto A, Brien E. Cytokines associated with the pathophysiology of aggressive fibromatosis. J Orthop Res 2000;18:655-62.
12. Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H, et al. β-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A 2002;99:6973-8. (Pubitemid 34526242)
13. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007;25:2648-59. (Pubitemid 47582758)
14. Fathke C, Wilson L, Hutter J, Kapoor V, Smith A, Hocking A, et al. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells 2004;22:812-22. (Pubitemid 39166938)
15. Wang G, Bunnell BA, Painter RG, Quiniones BC, Tom S, Lanson NA, et al. Adult stem cells from the bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci U S A 2005;102:186-91. (Pubitemid 40094450)
16. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007;87:858-70. (Pubitemid 47267815)
17. Metz CN. Fibrocytes: a unique cell population implicated in wound healing. Cell Mol Life Sci 2003;60:1342-50. (Pubitemid 36900518)
18. Opalenik SR, Davidson JM. Fibroblast differentiation of bone marrow-derived cells during wound repair. FASEB J 2005;19:1561-3. (Pubitemid 41279031)
19. Yang L, Scott PG, Medina A, Jiao H, Shankowsky HA, Ghahary A, et al. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 2005;13:398-404. (Pubitemid 41060421)
20. Moon JH, Kwak SS, Park G, Jung HY, Yoon BS, Park J, et al. Isolation and characterization of multipotent human keloid-derived mesenchymal stem cells. Stem Cells Dev 2008;17:713-24.
21. Akino K, Akita S, Yakabe A, Mineda Y, Hayashi T, Hirano A. Human mesenchymal stem cells may be involved in keloid pathogenesis. Int J Dermatol 2008;47:1112-7.
22. Hartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001;15:2215-24. (Pubitemid 32927939)
23. Moioli EK, Clark PA, Chen M, Dennis JE, Erickson HP, Gerson SL, et al. Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues. PLoS One 2008;3:e3922.
24. Wu Y, Zhao RC, Tredget EE. Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 2010;28:901-15.
25. Middleton SB, Frayling IM, Phillips RKS. Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br J Cancer 2000;82:827-32. (Pubitemid 30085234)
26. Li M, Cordon-Cardo C, Gerald WL, Rosai J. Desmoid fibromatosis is a clonal process. Hum Pathol 1996;27:939-43. (Pubitemid 26304573)
27. Bacac M, Migliavacca E, Stehle JC, McKee T, Delorenzi M, Coindre JM, et al. A gene expression signature that distinguishes desmoid tumours from nodular fasciitis. J Pathol 2006;208:543-53. (Pubitemid 43329341)
28. Denys H, De Wever O, Nusgens B, Kong Y, Sciot R, Le AT, et al. Invasion and MMP expression profile in desmoid tumours. Br J Cancer 2004;90:1443-9. (Pubitemid 38590640)
29. Nik SA, Ebrahim RP, Dam KV, Cassiman JJ, Teipar S. TGF-β modulates b-catenin stability and signaling in mesenchymal proliferations. Exp Cell Res 2007;313:2887-95.
30. Wu C, Nik-Amini S, Nadesan P, Stanford WL, Alman BA. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res 2010;70:7690-8.
31. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006;8:315-7. (Pubitemid 44269669)
32. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, et al. Ex vivo gylcan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008;14:181-7. (Pubitemid 351214550)
33. Deng J, Petersen BE, Steindler DA, Jorgensen ML, Laywell ED. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells 2006;24:1054-64. (Pubitemid 44464738)
34. Roelen BA, van Rooijen MA,Mummery CL. Expression of ALK1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn 1997;209:418-30. (Pubitemid 27328468)
35. Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy. Blood 2011;117:6999-7006.
36. Cho NL, Carothers AM, Rizvi H, Hasson RM, Redston M, Bertagnolli MM. Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. J Surg Res 2010 Nov 26. [Epub ahead of print].
37. Vazin T, Schaffer DV. Engineering strategies to emulate the stem cell niche. Trends Biotechnol 2009;28:117-24.
38. Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829-34.
39. Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transpl 2006;37:359-66. (Pubitemid 43250469)
40. Hoos A, Lewis JJ, Antonescu CR, Dudas ME, Leon L, Woodruff JM, et al. Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype - phenotype association in soft tissue tumors. Cancer Res 2001;61:3171-5. (Pubitemid 32691971)
41. Ross SE, Erickson RL, Gerin I, DeRose PM, Bajnok L, Longo KA, et al. Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor a in adipocyte metabolism. Mol Cell Biol 2002;22:5989-99. (Pubitemid 34815845)
42. Luis TC, Naber BAE, Roozen PPC, Brugman MH, de Haas EFE, Ghazvini M, et al. Canonical Wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell 2011;9:345-56.
43. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004;114:438-46. (Pubitemid 39071616)
44. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22. (Pubitemid 38437267)
45. Renström J, Istvanffy R, Gauthier K, Shimono A, Mages J, Jardon-Alvarez A, et al. Secreted Frizzled-related protein 1 extrinsically regulates cycling activity and maintenance of hematopoietic stem cells. Cell Stem Cell 2009;5:157-67.
46. Wielenga VJM, Smits R, Korinek V, Smit L, Kielman M, Fodde R, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the Wnt pathway. Am J Pathol 1999;154:515-23. (Pubitemid 29094101)
47. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, et al. ALK1 inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010;9:379-88.
48. Styner M, Sen B, Xie Z, Case N, Rubin J. Indomethacin promotes adipogenesis of mesenchymal stem cells through a cyclooxygenase independent mechanism. J Cell Biochem 2011;111:1042-50.
49. Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. J Cell Physiol 2011;226:322-30.